1. Home
  2. IOVA

as of 12-04-2025 4:00pm EST

$2.22
+$0.01
+0.45%
Stocks Health Care Biotechnology: Biological Products (No Diagnostic Substances) Nasdaq

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Chart Type:
Time Range:
Founded: 2007 Country:
United States
United States
Employees: N/A City: SAN CARLOS
Market Cap: 968.6M IPO Year: N/A
Target Price: $10.36 AVG Volume (30 days): 16.6M
Analyst Decision: Buy Number of Analysts: 12
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.20 EPS Growth: N/A
52 Week Low/High: $1.64 - $9.30 Next Earning Date: 11-06-2025
Revenue: $250,425,000 Revenue Growth: 175.62%
Revenue Growth (this year): 60.94% Revenue Growth (next year): 60.85%

AI-Powered IOVA Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold
Model Accuracy: 77.55%
77.55%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Share on Social Networks: